CoChat

Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma

Open access

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Purpose: Angiotensin system inhibitors (ASI) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant chemotherapy in resected PDAC patients. Experimental Design: We performed an analysis of the records of ASI users and nonuser patients with PDAC seen at Massachusetts General Hospital (Boston, MA) between January 2006 and December 2010. To identify mechanisms of ASIs in PDAC, we performed RNA sequencing (RNA-Seq) of resected primary lesions. Results: A total of 794 consecutive patients were included. In 299 resected patients, ASI users experienced longer overall survival (OS) in both univariate (median OS, 36.3 vs. 19.3 months, P = 0.011) and adjusted multivariate [HR, 0.505; 95% confidence interval (CI), 0.339–0.750; P = 0.001] analyses. Propensity score–adjusted analysis also showed a longer median OS for chronic ASI users. In unresected patients, the beneficial effect of ASIs was significant in patients with locally advanced disease, but not in metastatic patients. RNA-Seq analysis revealed in tumors of ASI users (lisinopril) a normalized extracellular matrix, a reduced expression of genes involved in PDAC progression (e.g., WNT and Notch signaling), and an increased expression of genes linked with the activity of T cells and antigen-presenting cells. Finally, chronic use of ASI was associated with a gene expression signature that is predictive of survival in independent validation cohorts. Conclusions: In patients with nonmetastatic PDAC, chronic ASI use is associated with longer OS independently of chemotherapy. Our RNA-Seq analysis suggests that ASIs reduce the malignant potential of cancer cells and stimulate the immune microenvironment in primary PDAC. Clin Cancer Res; 23(19); 5959–69. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0256

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 96

Metadata

Authors
Liu, H., Naxerova, K., Pinter, M., Incio, J., Lee, H., Shigeta, K., Ho, W. W., Crain, J. A., Jacobson, A., Michelakos, T., Dias-Santos, D., Zanconato, A., Hong, T. S., Clark, J. W., Murphy, J. E., Ryan, D. P., Deshpande, V., Lillemoe, K. D., Fernandez-del Castillo, C., Downes, M., Evans, R. M., Michaelson, J., Ferrone, C. R., Boucher, Y., & Jain, R. K.
Affiliations
  • Harvard University (US)
  • 1Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • 6Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Salk Institute for Biological Studies (US)
Corresponding author
  • Boucher, Yves
  • Jain, Rakesh K.
Venue
Clinical Cancer Research
Published
2017-10-01
Volume
23
Issue
19
Pages
5959-5969
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2623209858
Cited by
96
References
50
Citations by year
2026: 4 · 2025: 3 · 2024: 12 · 2023: 18 · 2022: 12 · 2021: 13 · 2020: 12 · 2019: 11 · 2018: 9 · 2017: 2
FWCI
4.10
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
  • Howard Hughes Medical Institute
  • American Association for Cancer Research
  • Austrian Science Fund
  • Ipsen
  • Stand Up To Cancer
  • National Cancer Institute (P01CA080124, R35CA197743, R01CA208205, P30CA014195)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Keywords
renin-angiotensin system inhibitors, pancreatic ductal adenocarcinoma, immune activation, overall survival, resected pancreatic cancer, adjuvant chemotherapy, lisinopril, tumor immune microenvironment, extracellular matrix, Wnt signaling, Notch signaling, T cells, gene expression signatures, prognostic factors
MeSH terms
Adenocarcinoma, Angiotensins, Antigen-Presenting Cells, Female, Humans, Male, Middle Aged, Neoplasm Proteins, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Disease-Free Survival, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0256
The paper
Liu, H., Naxerova, K., Pinter, M., Incio, J., Lee, H., Shigeta, K., Ho, W. W., Crain, J. A., Jacobson, A., Michelakos, T., Dias-Santos, D., Zanconato, A., Hong, T. S., Clark, J. W., Murphy, J. E., Ryan, D. P., Deshpande, V., Lillemoe, K. D., Fernandez-del Castillo, C., . . . Jain, R. K. (2017). Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.